School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Neuroscience Research Center, Iran University of Medical Sciences, Tehran, Iran.
Neurosurg Rev. 2024 Apr 22;47(1):177. doi: 10.1007/s10143-024-02424-x.
Antifibrinolytics have gained increasing attention in minimizing blood loss and mitigating the risks associated with massive transfusions, including infection and coagulopathy in pediatric patients undergoing spine surgery. Nevertheless, the selection of optimal agent is still a matter of debate. We aim to review the utility of these agents and compare the efficacy of antifibrinolytics in pediatric and adolescent spine surgeries. A comprehensive search was performed in Scopus, Web of Science, and MEDLINE databases for relevant works. Studies providing quantitative data on predefined outcomes were included. Primary outcome was perioperative bleeding between the groups. Secondary outcomes included transfusion volume, rate of complications, and operation time. Twenty-eight studies were included in the meta-analysis incorporating 2553 patients. The use of Tranexamic acid (RoM: 0.71, 95%CI: [0.62-0.81], p < 0.001, I = 88%), Aprotinin (RoM: 0.54, 95%CI: [0.46-0.64], p < 0.001, I = 0%), and Epsilon-aminocaproic acid (RoM: 0.71, 95%CI: [0.62-0.81], p < 0.001, I = 60%) led to a 29%, 46%, and 29% reduction in perioperative blood loss, respectively. Network meta-analysis revealed higher probability of efficacy with Tranexamic acid compared to Epsilon-aminocaproic acid (P score: 0.924 vs. 0.571). The rate of complications was not statistically different between each two antifibrinolytic agent or antifibrinolytics compared to placebo or standard of care. Our network meta-analysis suggests a superior efficacy of all antifibrinolytics compared to standard of care/placebo in reducing blood loss and transfusion rate. Further adequately-powered randomized clinical trials are recommended to reach definite conclusion on comparative performance of these agents and to also provide robust objective assessments and standardized outcome data and safety profile on antifibrinolytics in pediatric and adolescent pediatric surgeries.
抗纤维蛋白溶解剂在减少出血和降低儿科脊柱手术患者大量输血相关风险(包括感染和凝血功能障碍)方面受到越来越多的关注。然而,最佳药物的选择仍然存在争议。我们旨在回顾这些药物的作用,并比较抗纤维蛋白溶解剂在儿科和青少年脊柱手术中的疗效。在 Scopus、Web of Science 和 MEDLINE 数据库中进行了全面检索,以查找相关文献。纳入提供预定结局定量数据的研究。主要结局是两组之间的围手术期出血。次要结局包括输血量、并发症发生率和手术时间。Meta 分析纳入了 28 项研究,共 2553 例患者。使用氨甲环酸(RoM:0.71,95%CI:[0.62-0.81],p<0.001,I=88%)、抑肽酶(RoM:0.54,95%CI:[0.46-0.64],p<0.001,I=0%)和ε-氨基己酸(RoM:0.71,95%CI:[0.62-0.81],p<0.001,I=60%)可分别减少 29%、46%和 29%的围手术期出血量。网络荟萃分析显示,与ε-氨基己酸相比,氨甲环酸的疗效更高(P 评分:0.924 比 0.571)。与安慰剂或标准治疗相比,每种两种抗纤维蛋白溶解剂或抗纤维蛋白溶解剂之间的并发症发生率无统计学差异。我们的网络荟萃分析表明,与标准治疗/安慰剂相比,所有抗纤维蛋白溶解剂在减少出血量和输血率方面均具有更高的疗效。建议进一步开展充分的随机临床试验,以确定这些药物的相对疗效,并提供关于儿科和青少年儿科手术中抗纤维蛋白溶解剂的客观评估和标准化结局数据以及安全性概况。